Identification and characterization of survivin-derived H-2Kb-restricted CTL epitopes

European Journal of Immunology

Volumn 39, Issue 5, 2009, Pages 1419-1424

  Hofmann, Uta B ^a   Voigt, Heike ^a   Andersen, Mads H ^b   thor Straten, Per ^b   Becker, Jürgen C ^a   Eggert, Andreas O ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

DC; Melanoma; Murine; Survivin; Tcell

Indexed keywords

CANCER VACCINE; CYSTEINYLPHENYLALANYLPHENYLALANYLCYSTEINYLPHENYLALANYLLYSYLGLUTAMYLLEUCINE; DENDRITIC CELL VACCINE; SURVIVIN; THREONYLVALYLSERYLGLUTAMYLPHENYLALANYLLEUCYLLYSYLLEUCINE; UNCLASSIFIED DRUG; EPITOPE; H 2KB PROTEIN, MOUSE; H-2KB PROTEIN, MOUSE; H2 ANTIGEN; MICROTUBULE ASSOCIATED PROTEIN; SURVIVIN PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL KILLING; DENDRITIC CELL; FEMALE; IMMUNITY; IMMUNOGENICITY; IN VIVO STUDY; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SPLEEN CELL; SUBCUTANEOUS TISSUE TUMOR; T LYMPHOCYTE; ANIMAL; C57BL MOUSE; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; NEOVASCULARIZATION (PATHOLOGY); TUMOR CELL LINE;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, T-LYMPHOCYTE; FEMALE; H-2 ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MELANOMA; MICE; MICE, INBRED C57BL; MICROTUBULE-ASSOCIATED PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; T-LYMPHOCYTES, CYTOTOXIC;

EID: 67649950929     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.200839098     Document Type: Article

References (38)

1. Van den Eynde, B. J. and van der Bruggen, P., T cell defined tumor antigens. Curr. Opin. Immunol. 1997. 9: 684-693.
2. Mita, A. C., Mita, M. M., Nawrocki, S. T. and Giles, F. J., Survivin: Key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin. Cancer Res. 2008. 14: 5000-5005.
3. Ambrosini, G., Adida, C., Sirugo, G. and Altieri, D. C., Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J. Biol. Chem. 1998. 273: 11177-11182.
4. Adida, C., Haioun, C., Gaulard, P., Lepage, E., Morel, P., Briere, J., Dombret, H. et al., Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000. 96: 1921-1925.
5. Pisarev, V., Yu, B., Salup, R., Sherman, S., Altieri, D. C. and Gabrilovich, D. I., Full-length dominant-negative survivin for cancer immunotherapy. Clin. Cancer Res. 2003. 9: 6523-6533.
6. Andersen, M. H., Svane, I. M., Becker, J. C. and Straten, P. T., The universal character of the tumor-associated antigen survivin. Clin. Cancer Res. 2007. 13: 5991-5994.
7. Vetter, C. S., Muller-Blech, K., Schrama, D., Brocker, E. B. and Becker, J. C., Cytoplasmic and nuclear expression of survivin in melanocytic skin lesions. Arch. Dermatol. Res. 2005. 297: 26-30.
8. Islam, A., Kageyama, H., Takada, N., Kawamoto, T., Takayasu, H., Isogai, E., Ohira, M. et al., High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 2000. 19: 617-623.
9. Swana, H. S., Grossman, D., Anthony, J. N.,Weiss, R. M. and Altieri, D. C., Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N. Engl. J. Med. 1999. 341: 452-453.
10. Kawasaki, H., Altieri, D. C., Lu, C. D., Toyoda, M., Tenjo, T. and Tanigawa, N., Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1998. 58: 5071-5074.
11. Altieri, D. C., Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer 2003. 3: 46-54.
12. Krambeck, A. E., Dong, H., Thompson, R. H., Kuntz, S. M., Lohse, C. M., Leibovich, B. C., Blute, M. L. et al., Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. Clin. Cancer Res.. 2007. 13: 1749-1756.
13. Tran, J., Rak, J., Sheehan, C., Saibil, S. D., LaCasse, E., Korneluk, R. G. and Kerbel, R. S., Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem. Biophys. Res. Commun. 1999. 264: 781-788.
14. Harfouche, R., Hassessian, H. M., Guo, Y., Faivre, V., Srikant, C. B., Yancopoulos, G. D. and Hussain, S. N., Mechanisms which mediate the antiapoptotic effects of angiopoietin-1 on endothelial cells. Microvasc. Res. 2002. 64: 135-147.
15. Mesri, M., Morales-Ruiz, M., Ackermann, E. J., Bennett, C. F., Pober, J. S., Sessa, W. C. and Altieri, D. C., Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am. J. Pathol. 2001. 158: 1757-1765.
16. Kappler, M., Bache, M., Bartel, F., Kotzsch, M., Panian, M., Wurl, P., Blumke, K. et al., Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53. Cancer Gene Ther. 2004. 11: 186-193.
17. Grossman, D., McNiff, J. M., Li, F. and Altieri, D. C., Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J. Invest. Dermatol. 1999. 113: 1076-1081.
18. Ling, X. and Li, F., Silencing of antiapoptotic survivin gene by multiple approaches of RNA interference technology. Biotechniques 2004. 36: 450-460.
19. Andersen, M. H., Pedersen, L. O., Becker, J. C. and Straten, P. T., Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res. 2001. 61: 869-872.
20. Schmitz, M., Diestelkoetter, P., Weigle, B., Schmachtenberg, F., Stevanovic, S., Ockert, D., Rammensee, H. G. and Rieber, E. P., Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res. 2000. 60: 4845-4849.
21. Otto, K., Andersen, M. H., Eggert, A., Keikavoussi, P., Pedersen, L. O., Rath, J. C., Bock, M. et al., Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin. Vaccine2005. 23: 884-889.
22. Wobser, M., Keikavoussi, P., Kunzmann, V., Weininger, M., Andersen, M. H. and Becker, J. C., Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol. Immunother. 2006. 55: 1294-1298.
23. Li, F. and Altieri, D. C., The cancer antiapoptosis mouse survivin gene: Characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. Cancer Res. 1999. 59: 3143-3151.
24. Rammensee, H., Bachmann, J., Emmerich, N. P., Bachor, O. A. and Stevanovic, S., SYFPEITHI: Database for MHC ligands and peptide motifs. Immunogenetics 1999. 50: 213-219.
25. Eggert, A. O., Andersen, M. H., Voigt, H., Schrama, D., Kampgen, E., Straten, P. T. and Becker, J. C., Characterization of mouse MAGE-derived H-2Kb-restricted CTL epitopes. Eur. J. Immunol. 2004. 34: 3285-3290.
26. Andersen, M. H., Schrama, D., Thor,S. P. and Becker, J. C., Cytotoxic T cells. J. Invest. Dermatol. 2006. 126: 32-41.
27. Ciesielski, M. J., Kozbor, D., Castanaro, C. A., Barone, T. A. and Fenstermaker, R. A., Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma. Cancer Immunol. Immunother. 2008. 57: 1827-1835.
28. Folkman, J., Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med. 1971. 285: 1182-1186.
29. Xiang, R., Mizutani, N., Luo, Y., Chiodoni, C., Zhou, H., Mizutani, M., Ba, Y. et al., A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res. 2005. 65: 553-561.
30. Campoli, M., Chang, C. C. and Ferrone, S., HLA class I antigen loss, tumor immune escape and immune selection. Vaccine 2002. 20: A40-A45.
31. Andersen, M. H., Pedersen, L. O., Capeller, B., Brocker, E. B., Becker, J. C. and Thor, S. P., Spontaneous cytotoxic T-cell responses against survivinderived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res. 2001. 61: 5964-5968.
32. Reker, S., Meier, A., Holten-Andersen, L., Svane, I. M., Becker, J. C., Thor, S. P. and Andersen, M. H., Identification of novel survivin-derived CTL epitopes. Cancer Biol. Ther. 2004. 3: 173-179.
33. Siegel, S., Wagner, A., Schmitz, N. and Zeis, M., Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model. Br. J. Haematol. 2003. 122: 911-914.
34. Schrama, D., Xiang, R., Eggert, A. O., Andersen, M. H., Pedersen Ls, L. O., Kampgen, E., Schumacher, T. N. et al., Shift from systemic to site-specific memory by tumor-targeted IL-2. J. Immunol. 2004. 172: 5843-5850.
35. Schreurs, M. W., Eggert, A. A., de Boer, A. J., Vissers, J. L., van Hall, T., Offringa, R., Figdor, C. G. and Adema, G. J., Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model. Cancer Res. 2000. 60: 6995-7001.
36. Andersen, M. H., Sondergaard, I., Zeuthen, J., Elliott, T. and Haurum, J. S., An assay for peptide binding to HLA-Cw*0102. Tissue Antigens 1999. 54: 185-190.
37. Lutz, M. B., Kukutsch, N., Ogilvie, A. L., Rossner, S., Koch, F., Romani, N., and Schuler, G., An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods 1999. 223: 77-92.
38. Andersen, M. H., Bonfill, J. E., Neisig, A., Arsequell, G., Sondergaard, I., Valencia, G., Neefjes, J. et al., Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL. J. Immunol. 1999. 163: 3812-3818.